Personalized Medicine Could Shake Up Pharma

In the game of pharma, companies may have to give up on the home run known as the blockbuster drug—products like Lipitor and Avastin that were marketed to large swaths of the population and generated billions in sales—and hope that well-timed singles and doubles can carry the day.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.